tradingkey.logo

Beta Bionics Inc

BBNX
查看详细走势图
31.860USD
+0.770+2.48%
收盘 12/26, 16:00美东报价延迟15分钟
1.40B总市值
亏损市盈率 TTM

Beta Bionics Inc

31.860
+0.770+2.48%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+2.48%

5天

+8.92%

1月

+3.24%

6月

+112.54%

今年开始到现在

0.00%

1年

0.00%

查看详细走势图

TradingKey Beta Bionics Inc股票评分

单位: USD 更新时间: 2025-12-26

操作建议

Beta Bionics Inc当前公司基本面数据相对非常健康,增长潜力很大。当前估值合理,在医疗设备与耗材行业排名21/207位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价31.30。中期看,股价处于上升通道。近一个月,市场表现一般,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

Beta Bionics Inc评分

相关信息

行业排名
21 / 207
全市场排名
93 / 4563
所属行业
医疗设备与耗材

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

分析师目标

根据 10 位分析师
买入
评级
31.300
目标均价
+10.56%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Beta Bionics Inc亮点

亮点风险
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
业绩高增长
公司营业收入稳步增长,连续3年增长36282.12%
业绩增长期
公司处于发展阶段,最新年度总收入65.12M美元
估值低估
公司最新PE估值-16.40,处于3年历史低位
机构加仓
最新机构持股48.60M股,环比增加0.09%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓,最新持仓市值22.50K

Beta Bionics Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Beta Bionics Inc简介

Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
公司代码BBNX
公司Beta Bionics Inc
CEOSaint (Sean)
网址https://www.betabionics.com

常见问题

Beta Bionics Inc(BBNX)的当前股价是多少?

Beta Bionics Inc(BBNX)的当前股价是 31.860。

Beta Bionics Inc的股票代码是什么?

Beta Bionics Inc的股票代码是BBNX。

Beta Bionics Inc股票的52周最高点是多少?

Beta Bionics Inc股票的52周最高点是32.710。

Beta Bionics Inc股票的52周最低点是多少?

Beta Bionics Inc股票的52周最低点是8.890。

Beta Bionics Inc的市值是多少?

Beta Bionics Inc的市值是1.40B。

Beta Bionics Inc的净利润是多少?

Beta Bionics Inc的净利润为-54.76M。

现在Beta Bionics Inc(BBNX)的股票是买入、持有还是卖出?

根据分析师评级,Beta Bionics Inc(BBNX)的总体评级为买入,目标价格为31.300。

Beta Bionics Inc(BBNX)股票的每股收益(EPS TTM)是多少

Beta Bionics Inc(BBNX)股票的每股收益(EPS TTM)是-1.943。
KeyAI